Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Inclusion Criteria:

• Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
• Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
• Willing and able to provide written, signed informed consent
• Medically suitable for treatment with entrectinib (RXDX-101)

Exclusion Criteria:

• Currently enrolled in an ongoing clinical study with any other investigational agent